Microdosing Psilocybin for Beginners in 5 Easy Steps
Journal. Measure. Schedule. Listen. Flourish. This increasingly popular practice only pays off with careful intention and execution.
James Hallifax is an entrepreneur who co-founded The Psychedelic Investor, a media company focused on investing in psychedelic medicines which treat mental health conditions. Together with his business partner, they have grown their YouTube Channel to be the largest Channel dedicated to Investing in Psychedelics. Through their partnership with Psychedelic Spotlight, James aims to help educate retail investors on the potential for substances like LSD, MDMA and Magic Mushrooms to heal, and for early investors who make the right choices to make a lot of money. Rather than focus on day to day stock movements, James follows the underlying science of the industry, to help people understand which companies are the most likely to succeed long term.
Journal. Measure. Schedule. Listen. Flourish. This increasingly popular practice only pays off with careful intention and execution.
Compass Pathways (Nasdaq: CMPS) has announced the launch of a brand new psychedelic clinical trial, using psilocybin (the active ingredient in magic mushrooms) to treat PTSD, and there are multiple reasons to be excited about it. The Phase-2 clinical trial will use Comp 360, Compass Pathways’ proprietary synthetic crystalline psilocybin, paired with talk psychotherapy, in […]
Our resident psychedelic investor explains why psychedelic stocks are plummeting, and why patience can pay off big time.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.